Background: We report a case of myelopathy during the course of lupus profundus that is unique to our knowledge.
Case-report: A 29-year-old woman had lupus profundus since 1999, initially associated with thrombopenia (28,000 platelets/mm3) treated with corticosteroids for 6 months. Several nodular eruptions occurred from 1999 to 2004. Antinuclear antibodies were positive at 1/320 to 1/640 and complement C4 fraction was low. While being treated with hydroxychloroquine for a recent flare-up of nodular lesions of lupus profundus, she complained of paraesthesia of the abdominal wall and of the upper and lower limbs, suggestive of a medullary lesion. MRI disclosed an image of acute myelitis at the level of the second cervical vertebra. High doses of corticosteroids were promptly administered intravenously (methylprednisolone bolus) followed by oral prednisone and hydroxychloroquine. Six months later the patient was free of neurologic or cutaneous symptoms.
Discussion: In the literature, systemic signs are rarely associated with lupus profundus and myelitis has never been reported. Lupus myelitis is a vascular and/or demyelinating and usually segmental lesion of the spinal cord. Neurologic symptoms are those of acute rather than chronic or recurrent transverse myelitis. The prognosis is poor with frequent and severe functional sequelae. Treatment is mainly based on high-dose systemic corticotherapy alone or combined with cyclophosphamide. Our patient responded favourably to early methylprednisolone bolus followed by oral corticosteroids and antimalarial treatment.
Conclusion: Lupus profundus is classically of benign course with only cutaneous involvement, but it may sometimes be a sign of systemic lupus and in rare cases may be associated with severe complications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0151-9638(06)71083-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor necrosis factor-alpha (TNF-α) inhibitors are commonly used for management of various autoimmune disorders but can rarely cause isolated cutaneous lupus. This report presents two cases of cutaneous lupus erythematosus (LE) in women aged 38 and 61 after adalimumab treatment for psoriasis highlighting the importance of recognizing these paradoxical reactions for timely management.
View Article and Find Full Text PDFLupus mastitis is a presentation of lupus panniculitis that involves subcutaneous fat in patients with systemic lupus erythematosus (SLE). Moreover, lupus mastitis is a rare condition that typically presents as a palpable breast mass. Here, we report the case of a 29-year-old woman with a prior diagnosis of SLE who presented with palpable lumps in both breasts.
View Article and Find Full Text PDFA case report of lupus panniculitis-induced facial lipoatrophy successfully treated with injectable hyaluronic acid.
SAGE Open Med Case Rep
December 2024
Division of Dermatology, University of Calgary, Calgary, AB, Canada.
Article Synopsis
- Lupus panniculitis is a chronic form of cutaneous lupus that causes painful, firm nodules on areas like the legs, face, and trunk, potentially leading to scarring or loss of fat in those areas.
- Patients suffering from lipoatrophy due to lupus panniculitis may experience distress, and there is varying information on treating it with fat transfer or fillers.
- A case study highlights a 37-year-old woman who successfully restored volume in her right cheek using injectable hyaluronic acid filler after experiencing lipoatrophy following a period of stable disease.
Chronic Leg Ulcerations and Subcutaneous Panniculitis due to Dermal Herpes Zoster in an Immunosuppressed Woman.
J Cutan Pathol
February 2025
Joan C. Edwards School of Medicine, Marshall University, Huntington, West Virginia, USA.
Herpes zoster (HZ) is a cutaneous viral disease that typically presents with a dermatomal vesicular eruption. Immunosuppressed patients are more likely to have atypical HZ involving chronic ulceration and disseminated distribution, making diagnosis a challenge. The current report describes a unique case of HZ in a woman with systemic lupus on immunosuppressive therapy manifesting as persistent lower extremity ulceration with diffuse dermal and endothelial infection and secondary panniculitis without epidermal involvement.
View Article and Find Full Text PDFEpidemiology of Isolated Cutaneous Lupus Erythematosus in the Multiethnic Population of Reunion Island: A Retrospective Multicenter Study.
J Rheumatol
January 2025
L. Raffray, MD, PhD, Internal Medicine and Dermatology Unit, and UMR PIMIT "Processus Infectieux en Milieu Insulaire Tropical" CNRS 9192, INSERM 1187, IRD 249, Reunion Island University, Saint Denis, Reunion Island, France.
Article Synopsis
- * A total of 268 CLE cases were recorded, with a standardized prevalence of 43/100,000 and an estimated incidence of 5.7/100,000 person-years, showing higher rates compared to lighter-skinned populations.
- * Findings indicate that darker-skinned patients are more likely to experience severe forms of CLE and that certain clinical features may indicate a higher risk of progression to systemic lupus erythematosus (SLE), underscoring the need for tailored patient follow-up.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!